CNO Financial Group

CNONYSEUSD

THESIS ALERT

Email me when the CNO thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$57.93
+$0.15 (+0.26%)Today 1M +9.32%
After hours$57.930.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$57.78
Prior regular-session close from the quote source.
$57.39–$58.13
Regular-session low and high so far today.
477.1K
Regular-session shares traded · Nov 11, 4:00 PM ET.
Not yet confirmed
The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
$38.99–$59.15
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own CNO if CNO converts predictable premium cash flows from a diversified portfolio of health, life and annuity products into stable operating cash and shareholder capital by exercising underwriting discipline, expense control and conservative reserve/investment management.

CNO price history

Latest price$57.93Today+$0.15 (+0.26%)
CNO +8.61%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • CNO's underwriting and expense discipline will keep operating income roughly stable or modestly improving even as revenue grows, because pricing, claims management and expense leverage prevent margin erosion.StrengtheningMateriality: High

    operating_income rose from 459,500,000 (FY2023) to 550,800,000 (FY2024) and 553,200,000 (FY2025) while revenue increased — showing margin resilience. If true, predictable underwriting margins make earnings and capital returns reliable; if false, underwriting losses or expense creep will erode cash and force capital actions.

    Watch: A competitive price war in individual health/annuity markets that forces CNO to reduce premiums or accept worse risk pools.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    operating_income rose from 459,500,000 (FY2023) to 550,800,000 (FY2024) and 553,200,000 (FY2025) while revenue increased — showing margin resilience.

    Open source ↗
  • CNO converts underwriting profit and premium receipts into steadily rising operating cash flow, enabling predictable capital returns or reinvestment because of stable premium collections and claim/cost timing.StrengtheningMateriality: High

    operating_cash_flow increased each year: 495,400,000 (FY2022) → 582,900,000 (FY2023) → 627,700,000 (FY2024) → 675,700,000 (FY2025). Reliable operating_cash_flow funds dividends, buybacks or debt reduction without needing dilutive capital raises; if cash flow weakens, the company must cut returns or raise capital.

    Watch: A shift in persistency (higher lapses) or sudden change in premium collection timing that reduces float.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    operating_cash_flow increased each year: 495,400,000 (FY2022) → 582,900,000 (FY2023) → 627,700,000 (FY2024) → 675,700,000 (FY2025).

    Open source ↗
  • CNO's net income will remain volatile unless the company reduces reliance on realized investment gains/losses and reserve adjustments; investment and reserve swings are the primary driver of year-to-year net_income variability.HoldingMateriality: Medium

    net_income has swung materially: 630,600,000 (FY2022) → 276,500,000 (FY2023) → 420,800,000 (FY2024) → 229,300,000 (FY2025), indicating significant volatility. If not addressed, earnings volatility will keep valuation depressed despite healthy cash flow; if addressed, multiple expansion is likely.

    Watch: Sustained low investment yields or market downturns causing repeated realized losses.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    net_income has swung materially: 630,600,000 (FY2022) → 276,500,000 (FY2023) → 420,800,000 (FY2024) → 229,300,000 (FY2025), indicating significant volatility.

    Open source ↗
  • CNO's book equity can continue to grow through retained earnings if underwriting and cash conversion remain positive, supporting organic capital accumulation without frequent external capital raises.StrengtheningMateriality: Medium

    StockholdersEquity increased from 1,768,800,000 (FY2022) → 2,215,600,000 (FY2023) → 2,515,200,000 (FY2024) → 2,638,200,000 (FY2025), showing cumulative capital growth. Equity build reduces the need for dilutive capital raises and supports shareholder returns; if equity erodes, capital scarcity will pressure dividends or force issuance.

    Watch: Large negative net income periods or special charges that consume equity.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    StockholdersEquity increased from 1,768,800,000 (FY2022) → 2,215,600,000 (FY2023) → 2,515,200,000 (FY2024) → 2,638,200,000 (FY2025), showing cumulative capital growth.

    Open source ↗
  • Revenue growth will continue if CNO retains and expands distribution relationships and cross-sells across health, annuity and individual life products, because product diversification and agent/broker channels create multiple revenue levers.StrengtheningMateriality: Medium

    Revenue increased from 3,576,800,000 (FY2022) → 4,146,800,000 (FY2023) → 4,449,500,000 (FY2024) → 4,487,400,000 (FY2025), demonstrating top-line expansion. Sustained premium growth supports underwriting scale and expense leverage; loss of distribution or cross-sell ability would slow growth and reduce margin potential.

    Watch: Loss of major distribution partners or adverse shifts in broker economics that reduce new business.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Revenue increased from 3,576,800,000 (FY2022) → 4,146,800,000 (FY2023) → 4,449,500,000 (FY2024) → 4,487,400,000 (FY2025), demonstrating top-line expansion.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

CNO's underwriting and expense discipline will keep operating income roughly stable or modestly improving even as revenue grows, because pricing, claims management and expense leverage prevent margin erosion. If true, predictable underwriting margins make earnings and capital returns reliable; if false, underwriting losses or expense creep will erode cash and force capital actions.

CNO converts underwriting profit and premium receipts into steadily rising operating cash flow, enabling predictable capital returns or reinvestment because of stable premium collections and claim/cost timing. Reliable operating_cash_flow funds dividends, buybacks or debt reduction without needing dilutive capital raises; if cash flow weakens, the company must cut returns or raise capital.

CNO's net income will remain volatile unless the company reduces reliance on realized investment gains/losses and reserve adjustments; investment and reserve swings are the primary driver of year-to-year net_income variability. If not addressed, earnings volatility will keep valuation depressed despite healthy cash flow; if addressed, multiple expansion is likely.

CNO's book equity can continue to grow through retained earnings if underwriting and cash conversion remain positive, supporting organic capital accumulation without frequent external capital raises. Equity build reduces the need for dilutive capital raises and supports shareholder returns; if equity erodes, capital scarcity will pressure dividends or force issuance.

Revenue growth will continue if CNO retains and expands distribution relationships and cross-sells across health, annuity and individual life products, because product diversification and agent/broker channels create multiple revenue levers. Sustained premium growth supports underwriting scale and expense leverage; loss of distribution or cross-sell ability would slow growth and reduce margin potential.

All standing thesis claims
Original report summary

CNO converts predictable premium cash flows from a diversified portfolio of health, life and annuity products into stable operating cash and shareholder capital by exercising underwriting discipline, expense control and conservative reserve/investment management.

Evidence assessed Oct 19, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for CNO Financial Group

Where the evidence on CNO Financial Group stands: Holding on the latest evidence (Oct 19, 2026). Of its 5 thesis points, 4 strengthening and 1 holding.

Bull case: what the evidence supports

  • CNO's underwriting and expense discipline will keep operating income roughly stable or modestly improving even as revenue grows, because pricing, claims management and expense leverage prevent margin erosion.

    sec.gov ↗

  • CNO converts underwriting profit and premium receipts into steadily rising operating cash flow, enabling predictable capital returns or reinvestment because of stable premium collections and claim/cost timing.

    sec.gov ↗

  • CNO's net income will remain volatile unless the company reduces reliance on realized investment gains/losses and reserve adjustments; investment and reserve swings are the primary driver of year-to-year net_income variability.

    sec.gov ↗

  • CNO's book equity can continue to grow through retained earnings if underwriting and cash conversion remain positive, supporting organic capital accumulation without frequent external capital raises.

    sec.gov ↗

  • Revenue growth will continue if CNO retains and expands distribution relationships and cross-sells across health, annuity and individual life products, because product diversification and agent/broker channels create multiple revenue levers.

    sec.gov ↗

Bear case: what would count against it

  • A competitive price war in individual health/annuity markets that forces CNO to reduce premiums or accept worse risk pools.

    sec.gov ↗

  • A shift in persistency (higher lapses) or sudden change in premium collection timing that reduces float.

    sec.gov ↗

  • Sustained low investment yields or market downturns causing repeated realized losses.

    sec.gov ↗

Thesis-Break Engine

What has broken in CNO Financial Group’s thesis

Each break OptimistFi flagged on CNO Financial Group, dated — with what has historically followed the same kind of break across the market, not a forecast for CNO Financial Group.

peers+15%-13%+1%12 mo agonow+6 mo
Daily price, then where similar breaks led across the market: the typical +1% path vs comparable companies over six months, inside the middle-half range (+15% to -13%). A base rate, not a forecast.
  • Insider-selling clustercondition set before this filing

    Across all companies, this kind of break has happened 9,137 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 30% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against comparable companies after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Regulation FD disclosure.

    CNO Financial Group filed an SEC 8-K on 2026-09-01: Regulation FD disclosure. It is a dated development that tests the current thesis.

  2. Mixed
    Reported results of operations (earnings release).

    CNO Financial Group filed an SEC 8-K on 2026-07-30: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    CNO Financial Group filed an SEC 8-K on 2026-04-30: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • A competitive price war in individual health/annuity markets that forces CNO to reduce premiums or accept worse risk pools.
  • A shift in persistency (higher lapses) or sudden change in premium collection timing that reduces float.
  • Sustained low investment yields or market downturns causing repeated realized losses.
  • Large negative net income periods or special charges that consume equity.
  • Loss of major distribution partners or adverse shifts in broker economics that reduce new business.

CNO news

Loading headlines…

Financial statements

CNO income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

CNO: quick answers

Have members of Congress traded CNO?
3 trades in CNO have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed CNO trade
Which well-known investors own CNO?
1 of the 37 well-known funds tracked here reported CNO shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios

CNO in well-known investors’ portfolios

1 of 37 funds reported CNO shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.02%$4.5M−52.8%Q2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.